

# Yari Ciani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7005930/publications.pdf>

Version: 2024-02-01

28  
papers

3,622  
citations

331670

21  
h-index

501196

28  
g-index

30  
all docs

30  
docs citations

30  
times ranked

9476  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating RNAs in prostate cancer patients. <i>Cancer Letters</i> , 2022, 524, 57-69.	7.2	39
2	Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer. <i>Cell Systems</i> , 2022, 13, 183-193.e7.	6.2	13
3	Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4394-4403.	4.1	5
4	Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. <i>Nature Communications</i> , 2021, 12, 3297.	12.8	11
5	ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. <i>Bioinformatics</i> , 2020, 36, 2665-2674.	4.1	7
6	Two distinct immunopathological profiles in autopsy lungs of COVID-19. <i>Nature Communications</i> , 2020, 11, 5086.	12.8	230
7	Functional annotation of human long noncoding RNAs via molecular phenotyping. <i>Genome Research</i> , 2020, 30, 1060-1072.	5.5	109
8	High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids. <i>Oncotarget</i> , 2019, 8, e1614856.	4.6	25
9	HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 313.	8.6	67
10	An NF- $\kappa$ B signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells. <i>Neuro-Oncology</i> , 2018, 20, 776-787.	1.2	38
11	Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. <i>Oncotarget</i> , 2018, 9, 20508-20523.	1.8	86
12	A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action. <i>Nature Communications</i> , 2017, 8, 15772.	12.8	102
13	OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness. <i>Oncogene</i> , 2017, 36, 4253-4266.	5.9	40
14	Mammalian APE1 controls miRNA processing and its interactome is linked to cancer RNA metabolism. <i>Nature Communications</i> , 2017, 8, 797.	12.8	107
15	HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells. <i>Scientific Reports</i> , 2017, 7, 11768.	3.3	36
16	PIN1 in breast development and cancer: a clinical perspective. <i>Cell Death and Differentiation</i> , 2017, 24, 200-211.	11.2	51
17	Epigenetic silencing of miR-296 and miR-512 ensures hTERT dependent apoptosis protection and telomere maintenance in basal-type breast cancer cells. <i>Oncotarget</i> , 2017, 8, 95674-95691.	1.8	33
18	Effects of Pin1 Loss in HdhQ111 Knock-in Mice. <i>Frontiers in Cellular Neuroscience</i> , 2016, 10, 110.	3.7	15

#	ARTICLE	IF	CITATIONS
19	Critical role of lysosomes in the dysfunction of human Cardiac Stem Cells obtained from failing hearts. <i>International Journal of Cardiology</i> , 2016, 216, 140-150.	1.7	16
20	Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. <i>Nature Cell Biology</i> , 2016, 18, 897-909.	10.3	205
21	Translating Proteomic Into Functional Data: An High Mobility Group A1 (HMGA1) Proteomic Signature Has Prognostic Value in Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 109-123.	3.8	41
22	A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. <i>Oncotarget</i> , 2016, 7, 68012-68022.	1.8	110
23	A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. <i>Oncotarget</i> , 2015, 6, 19087-19101.	1.8	70
24	A promoter-level mammalian expression atlas. <i>Nature</i> , 2014, 507, 462-470.	27.8	1,838
25	Specific Mesothelial Signature Marks the Heterogeneity of Mesenchymal Stem Cells From High-Grade Serous Ovarian Cancer. <i>Stem Cells</i> , 2014, 32, 2998-3011.	3.2	16
26	miR-155 Drives Telomere Fragility in Human Breast Cancer by Targeting TRF1. <i>Cancer Research</i> , 2014, 74, 4145-4156.	0.9	108
27	HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. <i>Oncotarget</i> , 2013, 4, 1293-1308.	1.8	145
28	GTSE1 Is a Microtubule Plus-End Tracking Protein That Regulates EB1-Dependent Cell Migration. <i>PLoS ONE</i> , 2012, 7, e51259.	2.5	52